Dienestrol

Summary

Dienestrol (CHEMBL1018) is an approved small molecule (ATC G03CB01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G03CB01 (+1 more)
• Chemistry: 266.3 Da · C18H18O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1018
Name	Dienestrol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	667476
ATC	G03CB01, G03CC02
Molecular formula	C18H18O2
Molecular weight	266.3
InChIKey	NFDFQCUYFHCNBW-SCGPFSFSSA-N

SMILES: C/C=C(/C(=C/C)/C1=CC=C(C=C1)O)\C2=CC=C(C=C2)O

IUPAC name: 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol

Also known as: .alpha.-dienestrol diacetate, Cycladiene, Dehydrostilbestrol, Dienestrol, Dienestrol diacetate, .alpha.-, Dienestrol trans-form, Dienoestrol, Dienol, Dinovex, Dv, Estragard

Patent coverage: 1,997 distinct patent families (5,607 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Microtubule-associated protein tau, Prelamin-A/C, Ferritin light chain, Mitochondrial import inner membrane translocase subunit TIM10, Beta-lactamase, Glucocorticoid receptor, Estrogen receptor, Menin/Histone-lysine N-methyltransferase MLL, Delta-type opioid receptor, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 19 potent at pChembl ≥ 5 of 38 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ESR1	8.46	AC50	3.5	nM	CHEMBL_ACT_25167223
LMNA	8	Potency	10	nM	CHEMBL_ACT_3625700
P00811	6.5	Potency	316.2	nM	CHEMBL_ACT_4754486
NR3C1	6.13	AC50	736.3	nM	CHEMBL_ACT_25175753
CYP2C9	6.1	Potency	794.3	nM	CHEMBL_ACT_5065330
CYP2C9	6.1	AC50	794.3	nM	CHEMBL_ACT_5994380
LMNA	5.7	Potency	1995	nM	CHEMBL_ACT_3622823
CYP2C19	5.5	Potency	3162	nM	CHEMBL_ACT_4014216
CYP2C19	5.5	AC50	3162	nM	CHEMBL_ACT_6021962
ADORA3	5.14	AC50	7300	nM	CHEMBL_ACT_25134106
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_4977604
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_4993772
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_5046597
CYP3A4	5.1	Potency	7943	nM	CHEMBL_ACT_5062603
CYP3A4	5.1	AC50	7943	nM	CHEMBL_ACT_6022928
MAPT	5.05	Potency	8912	nM	CHEMBL_ACT_4509533
MAPT	5	Potency	10000	nM	CHEMBL_ACT_3943692
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4129658
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4518694

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).